- Company
- Janssen's young man who saved her life after a hit & run
- by Eo, Yun-Ho Nov 26, 2020 06:04am
- "When I got my mind, I knew I was under the car. I was just shouting for help, but someone talked to me." At eleven o'clock on the night of February 17, Ji Hyun-Joo (48 yrs old) Korea Johnson & Johnson (J&J), general director of Consumer Health Care AP, returned to the company (LS Yongsan Tower) after a dinner in late winter, when it was
- Policy
- ₩965 billion for COVID-19 vaccine should be reflected
- by Lee, Jeong-Hwan Nov 26, 2020 06:03am
- People Power Party Rep. Kang Ki-yoon, urged the Democratic Party of Korea and the government to reflect the cost of COVID-19 vaccine in next year's budget so that the nation can get COVID-19 vaccine. Earlier, a bill containing COVID-19 vaccine budget of &8361;965 billion was voted in the Budget Adjustment Subcommittee of the Health and W
- Product
- Struggling with dementia drug, Aβ-targeting drug unapproved
- by won-jong-hyuk Nov 26, 2020 06:03am
- Although many of Alzheimer's disease-targeting novel drugs are in development, the market is struggling to receive the health authority approval with troubles found during efficacy validation To this date, multinational pharmaceutical companies have initiated investigation on antibody agents targeting a number of therapeutic targets, such as
- Policy
- NSCLC treatment Vizimpro coverage effective from December
- by Lee, Hye-Kyung Nov 25, 2020 06:26am
- The healthcare reimbursement on Pfizer’s non-small cell lung cancer (NSCLC) treatment Vizimpro (dacomitinib) would be granted from Dec. 1. But the drug has to pass the Ministry of Health and Welfare (MOHW) Health Insurance Policy Deliberation Committee (HIPDC) on Nov. 27 to be fully approved. Prior to the HIPDC deliberation, the Health
- Company
- Yuhan secured ₩230 billion in two years
- by Chon, Seung-Hyun Nov 25, 2020 06:24am
- Yuhan has secured about &8361;230 billion in new drug technology fees over the past two years. It has signed five technology transfer contracts, and has also collected milestones of more than &8361;100 billion in the development stage after technology export. Yuhan announced on the 24th that it will receive a staged technology fee (milesto
- Policy
- The duration of administration of Maviret was reduced
- by Kim, Jung-Ju Nov 25, 2020 06:24am
- A plan to reduce the dosing period of Maviret (Glecaprevir/Pibrentasvir), a chronic hepatitis C virus treatment in Korea, from 12 weeks to 8 weeks in patients with chronic hepatitis 3 C infection in adults with targeted cirrhosis. Is promoted. Sumatriptan succinate, such as Myungin's migraine treatment Sumatran, doubles the daily reimbursed dose
- Company
- HCP and patients waiting for new T-cell lymphoma option
- by won, jong-hyuk Nov 25, 2020 06:24am
- The performances of anticancer therapies are improving as time goes by. But some cancer types still use chemotherapy as a standard of care (SOC) developed in 1970s to this date, regardless of the technological advancement in the anticancer area. One of them is Peripheral T-Cell Lymphoma (PTCL). Typically, PTCL is one kind of non-Hodgkin lymph
- Policy
- Full listed drug reevaluation subjects to be revealed soon
- by Kim, Jung-Ju Nov 24, 2020 09:04am
- The government plans to finalize and announce the list of second listed drug reimbursement feasibility evaluation (clinical reevaluation) and the first full-fledged reevaluation in next month. However, conducting the reevaluation using international reference pricing (IRP) would be physically impossible in a mean time, because of clashing op
- Company
- Atozet follow-on drugs conflicted over price manipulation
- by Chon, Seung-Hyun Nov 24, 2020 09:03am
- The South Korean dyslipidemia treatment Atozet market seems to be heating up with competition and conflict among consignment manufacturers. Companies in process of preparing for the Atozet generic have stated they would take a legal action against Chong Kun Dang’s violation of Fair Trade Act, claiming the Korean company is rigging the follow-on
- Policy
- Why Daewoong Bio tests Gliatirin as a comparator
- by Lee, Tak-Sun Nov 24, 2020 09:03am
- Gliatamin (Daewoong Bio), the No. 1 sales item in the brain function improvement drug Choline alfoscerate, which is drawing attention as a re-evaluation issue, was newly approved for a bioequivalence test. This bioequivalence test, which is conducted on products with improved formulations, is attracting more attention due to the recent
